Compare Incyte Corporation (INCY) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Teucrium Wheat Fund — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Teucrium Wheat Fund trades at $24.41 (market cap $273.67M). The key difference: Incyte Corporation is far larger — about 83.5× Teucrium Wheat Fund's market cap, and Teucrium Wheat Fund is more actively traded (222,576 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Teucrium Wheat Fund for 40 Days on average.
| INCY | WEAT | |
|---|---|---|
Market Cap | $22.85B | $273.67M |
Volume | 1,927,029 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.93 | $28.00 |
52-Week Low | $83.80 | $19.88 |
Typical Hold Time | 33 Days | 40 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
WEAT is trading at $24.41, down 1.97% with a bearish technical outlook as moving averages signal selling pressure. The wheat ETF faces mixed sentiment with recent price gains of 9.9% over the past month but current technical indicators showing weakness. Key support sits at $24 with resistance at $25, creating a tight trading range.
The ETF's performance remains tied to agricultural commodity volatility and inflation trends. Recent inflation data shows prices above Fed targets, potentially supporting commodity investments. However, technical weakness and the question of whether the recent rally is overdone present near-term challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
